Avalon Globocare (ALBT)
Market Price (1/27/2026): $0.7846 | Market Cap: $3.2 MilSector: Real Estate | Industry: Real Estate Services
Avalon Globocare (ALBT)
Market Price (1/27/2026): $0.7846Market Cap: $3.2 MilSector: Real EstateIndustry: Real Estate Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -36% | Weak multi-year price returns2Y Excs Rtn is -130%, 3Y Excs Rtn is -174% | Penny stockMkt Price is 0.8 |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Gene Editing & Therapy, Show more. | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -7.3 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -523% | |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 210% | ||
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 121% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -392%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -392% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -578% | ||
| High stock price volatilityVol 12M is 125% | ||
| Key risksALBT key risks include [1] potential Nasdaq delisting due to non-compliance with equity requirements, Show more. |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -36% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Gene Editing & Therapy, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -130%, 3Y Excs Rtn is -174% |
| Penny stockMkt Price is 0.8 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -7.3 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -523% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 210% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 121% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -392%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -392% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -578% |
| High stock price volatilityVol 12M is 125% |
| Key risksALBT key risks include [1] potential Nasdaq delisting due to non-compliance with equity requirements, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Avalon Globocare (ALBT) stock has lost about 65% since 9/30/2025 because of the following key factors:
1. Nasdaq Non-Compliance and Delisting Threat:Avalon Globocare (ALBT) faced significant pressure due to its prolonged non-compliance with Nasdaq's minimum stockholders' equity requirement. Nasdaq issued a formal notice of non-compliance on May 22, 2025, and a second "Staff Delisting Determination" on November 19, 2025, due to the company's negative stockholders' equity, which was well below the required $2.5 million minimum throughout 2025. This sustained threat of delisting created considerable uncertainty and likely contributed to a loss of investor confidence, weighing heavily on the stock price.
2. Dilutive All-Stock Acquisition to Regain Compliance:To resolve the Nasdaq compliance issue, Avalon executed "aggressive capital maneuvers," which included a "transformative $19.5 million acquisition" of the artificial intelligence software firm RPM Interactive, Inc. on December 15, 2025. This acquisition was an all-stock transaction, which typically leads to dilution for existing shareholders. The market reacted negatively to this event, with the stock experiencing a 24.63% drop around the acquisition date, as it was directly linked to efforts to boost equity for Nasdaq compliance. This move, while ultimately helping the company regain compliance by January 12, 2026, came at a cost to existing shareholders through dilution.
Show more
1. Nasdaq Non-Compliance and Delisting Threat:Avalon Globocare (ALBT) faced significant pressure due to its prolonged non-compliance with Nasdaq's minimum stockholders' equity requirement. Nasdaq issued a formal notice of non-compliance on May 22, 2025, and a second "Staff Delisting Determination" on November 19, 2025, due to the company's negative stockholders' equity, which was well below the required $2.5 million minimum throughout 2025. This sustained threat of delisting created considerable uncertainty and likely contributed to a loss of investor confidence, weighing heavily on the stock price.
2. Dilutive All-Stock Acquisition to Regain Compliance:To resolve the Nasdaq compliance issue, Avalon executed "aggressive capital maneuvers," which included a "transformative $19.5 million acquisition" of the artificial intelligence software firm RPM Interactive, Inc. on December 15, 2025. This acquisition was an all-stock transaction, which typically leads to dilution for existing shareholders. The market reacted negatively to this event, with the stock experiencing a 24.63% drop around the acquisition date, as it was directly linked to efforts to boost equity for Nasdaq compliance. This move, while ultimately helping the company regain compliance by January 12, 2026, came at a cost to existing shareholders through dilution.
Show more
Stock Movement Drivers
Fundamental Drivers
The -66.5% change in ALBT stock from 9/30/2025 to 1/27/2026 was primarily driven by a -46.9% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 9302025 | 1272026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.38 | 0.80 | -66.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 1 | 0.4% |
| P/S Multiple | 3.7 | 2.3 | -37.1% |
| Shares Outstanding (Mil) | 2 | 4 | -46.9% |
| Cumulative Contribution | -66.5% |
Market Drivers
9/30/2025 to 1/27/2026| Return | Correlation | |
|---|---|---|
| ALBT | -66.0% | |
| Market (SPY) | 4.4% | 16.9% |
| Sector (XLRE) | -2.1% | -1.4% |
Fundamental Drivers
The -71.3% change in ALBT stock from 6/30/2025 to 1/27/2026 was primarily driven by a -60.1% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 6302025 | 1272026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.78 | 0.80 | -71.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 1 | 2.0% |
| P/S Multiple | 3.3 | 2.3 | -29.5% |
| Shares Outstanding (Mil) | 2 | 4 | -60.1% |
| Cumulative Contribution | -71.3% |
Market Drivers
6/30/2025 to 1/27/2026| Return | Correlation | |
|---|---|---|
| ALBT | -70.9% | |
| Market (SPY) | 12.9% | 14.8% |
| Sector (XLRE) | 0.3% | -3.4% |
Fundamental Drivers
The -75.5% change in ALBT stock from 12/31/2024 to 1/27/2026 was primarily driven by a -77.3% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 12312024 | 1272026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.26 | 0.80 | -75.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 1 | 6.7% |
| P/S Multiple | 2.3 | 2.3 | 1.0% |
| Shares Outstanding (Mil) | 1 | 4 | -77.3% |
| Cumulative Contribution | -75.5% |
Market Drivers
12/31/2024 to 1/27/2026| Return | Correlation | |
|---|---|---|
| ALBT | -75.2% | |
| Market (SPY) | 19.7% | 14.3% |
| Sector (XLRE) | 3.8% | 2.7% |
Fundamental Drivers
The -99.0% change in ALBT stock from 12/31/2022 to 1/27/2026 was primarily driven by a -94.3% change in the company's P/S Multiple.| (LTM values as of) | 12312022 | 1272026 | Change |
|---|---|---|---|
| Stock Price ($) | 78.00 | 0.80 | -99.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 1 | 12.6% |
| P/S Multiple | 40.7 | 2.3 | -94.3% |
| Shares Outstanding (Mil) | 1 | 4 | -84.1% |
| Cumulative Contribution | -99.0% |
Market Drivers
12/31/2022 to 1/27/2026| Return | Correlation | |
|---|---|---|
| ALBT | -99.0% | |
| Market (SPY) | 88.6% | 4.2% |
| Sector (XLRE) | 22.6% | 1.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ALBT Return | -27% | -37% | -91% | -55% | -63% | -32% | -100% |
| Peers Return | 43% | -19% | -6% | 2% | 13% | 7% | 34% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 2% | 85% |
Monthly Win Rates [3] | |||||||
| ALBT Win Rate | 33% | 33% | 0% | 33% | 33% | 0% | |
| Peers Win Rate | 72% | 37% | 43% | 50% | 60% | 80% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 100% | |
Max Drawdowns [4] | |||||||
| ALBT Max Drawdown | -27% | -61% | -92% | -69% | -73% | -32% | |
| Peers Max Drawdown | -2% | -38% | -22% | -18% | -18% | -1% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: LH, DGX, CRL, BIO, GILD.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 1/27/2026 (YTD)
How Low Can It Go
| Event | ALBT | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -97.5% | -25.4% |
| % Gain to Breakeven | 3827.9% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -57.1% | -33.9% |
| % Gain to Breakeven | 133.1% | 51.3% |
| Time to Breakeven | 57 days | 148 days |
| 2018 Correction | ||
| % Loss | -88.5% | -19.8% |
| % Gain to Breakeven | 771.5% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
Compare to LH, DGX, CRL, BIO, GILD
In The Past
Avalon Globocare's stock fell -97.5% during the 2022 Inflation Shock from a high on 2/16/2021. A -97.5% loss requires a 3827.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Avalon Globocare (ALBT)
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.
AI Analysis | Feedback
An early-stage Kite Pharma (now part of Gilead Sciences), developing novel cell and gene therapies for cancer.
A clinical-stage bluebird bio, focused on advanced cell and gene therapies for oncology and regenerative medicine.
Think of it as a startup Moderna or CRISPR Therapeutics, but specializing in cell-based therapies for cancer.
AI Analysis | Feedback
- Biotechnology & Pharmaceutical Drug Development: Engages in the research and development of novel therapeutic candidates, primarily focused on immune-oncology and cellular therapies for various diseases.
- Medical Diagnostics: Develops and commercializes rapid diagnostic tests and related platforms for disease detection and monitoring.
- Regenerative Medicine: Focuses on advancing technologies and treatments, including cell therapies, aimed at repairing or replacing damaged tissues and organs.
AI Analysis | Feedback
Avalon Globocare (ALBT) operates across multiple business segments, including healthcare services, medical supplies distribution, environmental services, and information technology. According to its public filings, including the 10-K for the fiscal year ended June 30, 2023, no single customer accounted for 10% or more of its total revenue. Therefore, the company does not disclose specific "major customers" by name.
However, Avalon Globocare serves a diverse range of customers that can be categorized as follows:
Categories of Customers:
- Other Healthcare Providers and Institutions: This category primarily encompasses hospitals, clinics, diagnostic laboratories (that refer specimens to ALBT's labs), physicians' offices, and other medical practices. These entities utilize ALBT's diagnostic services, medical equipment, and supplies distribution.
- Governmental, Industrial, and Commercial Clients: This broad category includes government agencies (for medical supplies and environmental services), industrial businesses, and various commercial enterprises. These clients primarily utilize ALBT's environmental business offerings (such as waste management, recycling, and renewable energy solutions) and its information technology services.
- Individuals (Patients): Avalon Globocare serves individuals directly through its owned and operated primary and specialty care medical practices. Patients seeking medical consultations, diagnoses, and treatments fall into this customer category.
AI Analysis | Feedback
null
AI Analysis | Feedback
Dr. David Jin, M.D., Ph.D., Chief Executive Officer, President & Director
Dr. David Jin co-founded Avalon GloboCare Corp. and has served as its CEO since September 2016. From 2009 to 2016, he was the Chief Medical Officer of BioTime, Inc. (now Lineage Cell Therapeutics), a clinical-stage regenerative medicine company focused on pluripotent stem cell technology. He is also a senior translational clinician-scientist at the Howard Hughes Medical Institute and the Ansary Stem Cell Center at Weill Cornell Medical College. Prior to these roles, Dr. Jin acted as Chief Consultant/Advisor for various biotech/pharmaceutical companies, specializing in hematology, oncology, immunotherapy, and stem cell technology development.
Luisa Ingargiola, Chief Financial Officer & Principal Accounting Officer
Ms. Ingargiola brings significant experience as a Chief Financial Officer and Audit Chair for numerous NASDAQ and NYSE-listed companies. She currently holds Director and Audit Chair positions for public companies such as ElectraMeccanica (NASDAQ:SOLO), Dragonfly Energy (NASDAQ:DFLI), and Vision Marine Technologies (NASDAQ:VMAR). From 2007 to 2016, she served as the CFO and later a Director at MagneGas Corporation (Nasdaq: MNGA). Before 2007, Ms. Ingargiola held various roles as Budget Director and Investment Analyst within several private companies.
Meng Li, Chief Operating Officer & Secretary
Ms. Li possesses over 15 years of executive experience in international marketing, branding, communications, and media investment consultancy. Her previous roles include serving as Managing Director at Maxus/GroupM (a WPP Group company) from 2006 to 2015 and as a Senior Manager at Zenith Media (a Publicis Group company) from 2000 to 2006.
Wenzhao Lu, Chairman of the Board
Mr. Lu is a seasoned healthcare entrepreneur with extensive operational experience in China. Since 2010, he has served as the Chairman of the Board for the DaoPei Medical Group, under whose leadership the group expanded its clinical network to include a stem cell bank, three top-ranked private hospitals, specialty hematology laboratories, and a research institute. Mr. Lu has also provided a revolving line of credit to Avalon GloboCare.
AI Analysis | Feedback
Avalon Globocare (ALBT) faces several significant risks to its business, primarily stemming from its financial health and operational standing.
- Nasdaq Delisting Risk: Avalon Globocare has been notified multiple times of non-compliance with Nasdaq's minimum stockholders' equity requirement. The company's stockholders' equity has been reported as negative, and it has failed to meet alternative compliance standards related to market value and net income. While a recent acquisition was intended to address this, the company's compliance status is described as a belief rather than a final regulatory order, and the stock experienced a significant decline following the news. Delisting could severely impact the stock's liquidity and the company's ability to raise capital.
- Significant Financial Weakness and Liquidity Issues: The company exhibits substantial financial instability, including widening losses and a significantly negative operating margin of -522.7%. Its current ratio of 0.19 indicates significant liquidity challenges. Furthermore, the company has experienced negative free cash flow and has no support from accumulated volume below current levels, suggesting a potential for further significant stock depreciation. The stock is also considered "very high risk" due to high volatility and periodic low trading volume.
- Uncertainty in Business Model and Lack of Clear Catalysts: Avalon Globocare operates with two reportable segments: real property and laboratory testing services, focusing on diagnostic and therapeutic areas in biotech. Despite this, the company faces a lack of pipeline visibility, partnership momentum, and near-term catalysts, contributing to a grim near-term outlook for the stock. Its stock performance has diverged significantly from the broader biotech sector, and its falling revenue further underscores an unclear path to sustainable growth and profitability.
AI Analysis | Feedback
The rapid advancement and potential market penetration of allogeneic (off-the-shelf) CAR-T and CAR-NK cell therapies by competitors represents a clear emerging threat. These allogeneic therapies promise significant advantages over autologous (patient-specific) treatments, such as simplified manufacturing, reduced turnaround time, lower costs, and greater patient accessibility. Numerous companies are actively developing and progressing these off-the-shelf candidates through clinical trials, with some programs already in later stages for oncology indications. Should these allogeneic therapies achieve regulatory approval and demonstrate comparable or superior safety and efficacy, they could fundamentally disrupt the market for autologous cell therapies, thereby significantly limiting the market opportunity and competitive positioning for Avalon Globocare's current pipeline, which largely focuses on autologous approaches.
AI Analysis | Feedback
Avalon Globocare (ALBT) operates in several key areas, including cell-based therapeutics (specifically CAR T-cell therapy), exosome technology for diagnostics and therapeutics, and precision diagnostics, which encompasses proprietary devices like KetoAir, AI Nutritionist software, and general clinical laboratory services.
Addressable Markets:
- CAR T-cell Therapy: The global CAR T-cell therapy market was estimated at approximately $4.65 billion in 2024 and is projected to reach around $15.97 billion by 2030. Another estimate values the global market at $4.3 billion in 2024, with a projection to grow to $23.25 billion by 2034. In the U.S. alone, the market for CAR T-cell therapy was valued at $2.005 billion in 2024 and is expected to grow to approximately $9.96 billion by 2034.
- Exosome Technology (Therapeutics and Diagnostics): The global exosome therapeutics market was valued at $1.26 billion in 2024 and is anticipated to increase to $3.71 billion by 2035. Another source indicates the global exosome diagnostic and therapeutic market was valued at $224.34 million in 2020 and is projected to reach $2.9 billion by 2030. The global market for exosome diagnostics, therapeutics, and research tools was estimated at $227.5 million in 2023 and is projected to reach $1.3 billion by 2028.
- Precision Diagnostics & Clinical Laboratory Services: Avalon Globocare is involved in precision diagnostics and clinical laboratory services. Specific market sizes for their KetoAir device or AI Nutritionist software are not readily available.
AI Analysis | Feedback
Avalon Globocare (ALBT) is expected to drive future revenue growth over the next 2-3 years through several key initiatives:
- Strategic Acquisitions and Expansion of Laboratory Services: Avalon Globocare's commercial strategy emphasizes laboratory acquisitions and diagnostics, aiming to capitalize on a "roll-up opportunity" in the fragmented market for laboratory testing and services. An example of this strategy is the acquisition of a 40% interest in Laboratory Services MSO (LSM) in February 2023. LSM has since expanded its service offerings and is actively evaluating additional accretive acquisitions, which are anticipated to generate significant future cash flow for Avalon through a profit-sharing arrangement.
- Commercialization and Distribution of the KetoAir Breathalyzer: The company has secured exclusive distribution rights for the KetoAir breathalyzer device and its accessories, and is actively progressing toward its commercialization. Avalon Globocare has been exploring various commercialization options, including identifying distribution partners and direct distribution. Recent developments include the launch of online sales for KetoAir in the United Kingdom and a distribution agreement with Saga Health to target first responders.
- Advancements and Commercialization of Precision Diagnostics and Proprietary Technologies: Avalon Globocare is committed to leading innovation in diagnostic testing by utilizing proprietary technology to deliver precise, genetics-driven results. The company is developing a fusion gene map technology for leukemia, with a diagnostic prototype projected to enter clinical studies in Q3 2023. Additionally, Avalon Globocare has been granted patents for novel CAR-T and CAR-NK cell technology in Hong Kong and China. They are also co-developing a real-time cannabis breathalyzer with Qi Diagnostics, demonstrating a pipeline of innovative diagnostic products.
- Formation of Strategic Alliances and Partnerships: The company is actively pursuing and entering into strategic alliances to expand its market reach and develop new revenue streams. Examples include partnerships with Qi Diagnostics for the co-development of a cannabis breathalyzer, and with SpecialtyHealth, Inc. to utilize KetoAir for the Police Chiefs' Fitness Challenge. Avalon Globocare also pursued a proposed merger with YOOV, a provider of business AI automation solutions. These collaborations are crucial for leveraging external expertise and broadening the company's offerings.
AI Analysis | Feedback
Share Issuance
- Avalon GloboCare entered into a securities purchase agreement on July 23, 2025, to issue and sell 300 shares of Series C Convertible Preferred Stock for a total of $300,000 to Mast Hill Fund, L.P., with expected net proceeds of $290,000.
- The company issued two convertible promissory notes, each valued at $100,000, to accredited investors on July 3, 2025.
- Between July 30, 2025, and August 6, 2025, Avalon GloboCare issued 221,000 shares of unregistered common stock to a noteholder through partial conversions of an outstanding promissory note.
- On July 14, 2025, Avalon GloboCare entered into a deal to sell 121,200 shares and pre-funded warrants for 354,300 shares to Brown Stone Capital Ltd. for $475,500, with net proceeds of $450,500.
Inbound Investments
- Mast Hill Fund, L.P. made an investment by purchasing $300,000 in Series C Convertible Preferred Stock from Avalon GloboCare in July 2025.
- Accredited investors provided inbound investment through two convertible promissory notes, each for $100,000, in July 2025.
Outbound Investments
- Avalon GloboCare acquired a 40% interest in Laboratory Services MSO LLC in 2022.
Capital Expenditures
- The company's future funding requirements include financing capital expenditures and general and administrative expenses.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Avalon Globocare Earnings Notes | 12/16/2025 | |
| Avalon Globocare Stock Drop Looks Sharp, But How Deep Can It Go? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 201.87 |
| Mkt Cap | 15.7 |
| Rev LTM | 7,437 |
| Op Inc LTM | 860 |
| FCF LTM | 962 |
| FCF 3Y Avg | 747 |
| CFO LTM | 1,276 |
| CFO 3Y Avg | 1,101 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 4.7% |
| Rev Chg 3Y Avg | 2.3% |
| Rev Chg Q | 2.2% |
| QoQ Delta Rev Chg LTM | 0.6% |
| Op Mgn LTM | 9.4% |
| Op Mgn 3Y Avg | 11.8% |
| QoQ Delta Op Mgn LTM | 0.3% |
| CFO/Rev LTM | 18.0% |
| CFO/Rev 3Y Avg | 15.4% |
| FCF/Rev LTM | 13.0% |
| FCF/Rev 3Y Avg | 10.0% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 15.7 |
| P/S | 2.5 |
| P/EBIT | 14.7 |
| P/E | 10.6 |
| P/CFO | 13.5 |
| Total Yield | 2.0% |
| Dividend Yield | 0.5% |
| FCF Yield 3Y Avg | 5.1% |
| D/E | 0.3 |
| Net D/E | 0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 6.0% |
| 3M Rtn | 4.3% |
| 6M Rtn | 14.3% |
| 12M Rtn | 13.6% |
| 3Y Rtn | -0.8% |
| 1M Excs Rtn | 5.2% |
| 3M Excs Rtn | -3.3% |
| 6M Excs Rtn | 4.9% |
| 12M Excs Rtn | 1.8% |
| 3Y Excs Rtn | -76.4% |
Price Behavior
Price Behavior
| Market Price | $0.81 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 03/16/2018 | |
| Distance from 52W High | -92.6% | |
| 50 Days | 200 Days | |
| DMA Price | $1.28 | $2.39 |
| DMA Trend | down | down |
| Distance from DMA | -36.9% | -66.2% |
| 3M | 1YR | |
| Volatility | 128.9% | 125.8% |
| Downside Capture | 476.80 | 187.25 |
| Upside Capture | -96.20 | 12.34 |
| Correlation (SPY) | 14.6% | 12.9% |
ALBT Betas & Captures as of 12/31/2025
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 7.84 | 2.95 | 2.09 | 1.86 | 0.98 | 0.65 |
| Up Beta | 16.48 | -2.72 | -1.12 | -0.03 | 0.26 | -0.92 |
| Down Beta | 8.24 | 3.66 | 2.68 | 1.84 | 1.44 | 1.27 |
| Up Capture | 503% | 177% | 62% | 100% | 59% | -0% |
| Bmk +ve Days | 11 | 23 | 37 | 72 | 143 | 431 |
| Stock +ve Days | 7 | 15 | 24 | 53 | 106 | 304 |
| Down Capture | 744% | 477% | 341% | 292% | 144% | 111% |
| Bmk -ve Days | 11 | 18 | 27 | 55 | 108 | 320 |
| Stock -ve Days | 14 | 25 | 36 | 68 | 134 | 422 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ALBT | |
|---|---|---|---|---|
| ALBT | -75.4% | 125.6% | -0.52 | - |
| Sector ETF (XLRE) | 1.6% | 16.4% | -0.08 | 2.4% |
| Equity (SPY) | 15.5% | 19.3% | 0.62 | 12.7% |
| Gold (GLD) | 87.8% | 20.6% | 2.98 | 2.4% |
| Commodities (DBC) | 10.6% | 15.5% | 0.45 | -3.7% |
| Real Estate (VNQ) | 3.6% | 16.5% | 0.04 | 2.0% |
| Bitcoin (BTCUSD) | -15.6% | 39.7% | -0.33 | 14.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ALBT | |
|---|---|---|---|---|
| ALBT | -62.6% | 188.8% | 0.03 | - |
| Sector ETF (XLRE) | 5.6% | 19.0% | 0.20 | 4.6% |
| Equity (SPY) | 14.1% | 17.1% | 0.66 | 7.5% |
| Gold (GLD) | 22.3% | 15.7% | 1.14 | 4.3% |
| Commodities (DBC) | 12.3% | 18.7% | 0.53 | -0.4% |
| Real Estate (VNQ) | 4.8% | 18.8% | 0.16 | 5.1% |
| Bitcoin (BTCUSD) | 20.0% | 57.9% | 0.55 | 5.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ALBT | |
|---|---|---|---|---|
| ALBT | -41.2% | 175.9% | 0.14 | - |
| Sector ETF (XLRE) | 6.9% | 20.5% | 0.30 | 8.1% |
| Equity (SPY) | 15.8% | 17.9% | 0.76 | 10.2% |
| Gold (GLD) | 16.5% | 14.9% | 0.92 | 4.1% |
| Commodities (DBC) | 8.9% | 17.6% | 0.42 | 1.4% |
| Real Estate (VNQ) | 5.9% | 20.8% | 0.25 | 8.7% |
| Bitcoin (BTCUSD) | 72.5% | 66.5% | 1.11 | 5.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 4/27/2023 | 0.5% | 0.0% | -8.9% |
| SUMMARY STATS | |||
| # Positive | 1 | 1 | 0 |
| # Negative | 0 | 0 | 1 |
| Median Positive | 0.5% | 0.0% | |
| Median Negative | -8.9% | ||
| Max Positive | 0.5% | 0.0% | |
| Max Negative | -8.9% | ||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 03/31/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/19/2024 | 10-Q |
| 03/31/2024 | 05/31/2024 | 10-Q |
| 12/31/2023 | 04/15/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/22/2023 | 10-Q |
| 12/31/2022 | 03/30/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/05/2022 | 10-Q |
| 03/31/2022 | 05/11/2022 | 10-Q |
| 12/31/2021 | 03/30/2022 | 10-K |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.